Table 2 Geometric means and 95% C.I. of antibody titers (IU/mL) in the maternal specimens analyzeda.

From: Humoral response to anti-SARS-CoV-2 vaccine in breastfeeding mothers and mother-to-infant antibody transfer through breast milk

IgG geometric mean (95% C.I.)

  

T0

T1

T2

T3

T4

Serum

Anti-S

22.37

(19.46–25.71)

160.6

(119.00–216.80)

581.9

(486.50–696)

507.2

(394.80–651.70)

357

(284.50–447.90)

Anti-RBD

42.28

(41.49–43.08)

338.7

(253.50–452.40)

1089

(928.80–1278)

908.8

(752.20–1098)

703.3

(544.60–908.20)

Saliva

Anti S

0.26

(0.26–0.27)

0.33

(0.29–0.38)

0.5

(0.40–0.62)

0.37

(0.33–0.41)

0.32

(0.31–0.33)

Anti-RBD

1.12

(1.12–1.12)

1.10

(1.03–1.17)

1.99

(1.53–2.57)

1.32

(1.14–1.53)

1.13

(1.08–1.18)

Breast milk

Anti-S

2.04

(2.03–2.05)

2.17

(2.10–2.25)

3.78

(3.11–4.60)

2.97

(2.47–3.56)

2.52

(2.26–2.82)

Anti-RBD

4.06

(4.03–4.09)

4.42

(4.10–4.77)

9.19

(6.83–12.40)

6.21

(5.12–7.53)

5.02

(4.41–5.71)

IgA geometric mean (95% C.I.)

  

T0

T1

T2

T3

T4

Serum

Aanti-S

45.2

(37.89–53.93)

119.1

(73.81–192.1)

87

(66.36–114.1)

81.09

(61.46–107)

69.54

(53.25–90.81)

Anti-RBD

54.73

(34.22–87.52)

84.75

(39.22–183.1)

160.3

(94.25–272.7)

61.13

(23.89–156.4)

35.04

(14.57–84.31)

Saliva

Anti S

1.14

(0.973–1.33)

2.049

(1.40–3.01)

1.75

(1.47–2.08)

1.659

(1.27–2.17)

1.569

(1.28–1.92)

Anti-RBD

0.23

(0.054–0.92)

1.69

(0.76–3.73)

1.43

(0.65–3.17)

0.92

(0.35–2.41)

0.91

(0.36–2.28)

Breast milk

Anti-S

8.54

(6.56–11.19)

13.37

(8.68–20.59)

12.88

(7.72–21.49)

11.95

(7.06–20.22)

12.87

(7.62–21.74)

Anti-RBD

11.13

(7.97–15.54)

20.58

(14.76–28.68)

18.12

(12.78–25.68)

15.75

(10.54–23.53)

16.67

(11.25–24.7)

  1. aNo. of missing samples: 2 breast milks at T3, 2 breast milks at T4, 2 sera at T3, 2 sera at T4, 15 saliva at T0, 3 saliva at T1, 2 saliva at T3, 2 saliva at T4.